

Retraction: Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21^{CIP1} Down-Regulation

The article entitled, "Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21^{CIP1} Down-Regulation," which was published in the July 15, 2007, issue of *Clinical Cancer Research* [CCR (1)], is being retracted at the request of the AACR Publications Department and the CCR Editor-in-Chief and Executive Editor. The AACR Publications Department received a letter from the U.S. Department of Health and Human Services' Office of Research Integrity (ORI) in which it stated that Girija Dasmahapatra, the first author of the above-mentioned article, engaged in research misconduct by "falsifying and/or fabricating data" that appeared in the 2007 article. ORI provided the editors with image analyses for Fig. 3B (PARP) and Fig. 6A (Tubulin). An excerpt of the response from ORI regarding the analyses is as follows:

"The analysis would show that the Western blots were falsely relabeled and re-used in multiple publications to represent the results of experiments with different cell lines under different conditions/treatments. In some instances, the original data for the reported experiments do not exist, and in other instances, control blots were not run and were substituted indiscriminately from other experiments, regardless of the cell line or conditions/treatments used."

The matter was reviewed by members of the AACR Publications staff and the CCR editors, who agree that the figure manipulation present in the article merits retraction. All five authors have consented to this retraction.

Reference

1. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21^{CIP1} down-regulation. *Clin Cancer Res* 2007;13:4280-90.

Published online October 3, 2016.

doi: 10.1158/1078-0432.CCR-16-1914

©2016 American Association for Cancer Research.

Clinical Cancer Research

Retraction: Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation

Clin Cancer Res 2016;22:4959.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/19/4959>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/22/19/4959.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/22/19/4959>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.